- Home
- JANX vs RDFN Comparison
JANX vs RDFN Comparison
Compare JANX & RDFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- RDFN
- Stock Information
- Founded
- JANX 2017
- RDFN 2002
- Country
- JANX United States
- RDFN United States
- Employees
- JANX N/A
- RDFN N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- RDFN Real Estate
- Sector
- JANX Health Care
- RDFN Finance
- Exchange
- JANX Nasdaq
- RDFN Nasdaq
- Market Cap
- JANX 1.6B
- RDFN 1.3B
- IPO Year
- JANX 2021
- RDFN 2017
- Fundamental
- Price
- JANX $23.60
- RDFN $11.24
- Analyst Decision
- JANX Strong Buy
- RDFN Hold
- Analyst Count
- JANX 7
- RDFN 11
- Target Price
- JANX $94.29
- RDFN $10.85
- AVG Volume (30 Days)
- JANX 808.2K
- RDFN 6.4M
- Earning Date
- JANX 08-06-2025
- RDFN 08-05-2025
- Dividend Yield
- JANX N/A
- RDFN N/A
- EPS Growth
- JANX N/A
- RDFN N/A
- EPS
- JANX N/A
- RDFN N/A
- Revenue
- JANX $9,336,000.00
- RDFN $1,038,527,000.00
- Revenue This Year
- JANX N/A
- RDFN N/A
- Revenue Next Year
- JANX $1,470.82
- RDFN $5.32
- P/E Ratio
- JANX N/A
- RDFN N/A
- Revenue Growth
- JANX 28.12
- RDFN 5.11
- 52 Week Low
- JANX $22.48
- RDFN $5.49
- 52 Week High
- JANX $71.71
- RDFN $15.29
- Technical
- Relative Strength Index (RSI)
- JANX 41.60
- RDFN 64.56
- Support Level
- JANX $24.45
- RDFN $10.29
- Resistance Level
- JANX $27.28
- RDFN $11.09
- Average True Range (ATR)
- JANX 1.35
- RDFN 0.50
- MACD
- JANX -0.09
- RDFN 0.06
- Stochastic Oscillator
- JANX 22.20
- RDFN 91.98
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments real estate services, rentals, mortgage, title, and monetization. The company generates the majority of its revenue from Real estate services.